Neoolife is revolutionizing Heart Valve Therapy with its cutting-edge proprietary DCD tissue engineering technology, leading to unique biomimetic polymeric heart valves, like Neoolife´s OneValveTric, the next-gen solution for percutaneous Tricuspid Valve Replacement.
DCD tissue-engineered Biomimetic Polymeric Heart Valves are non-animal-derived, metal-free, and available in non-resorbable (permanent) and resorbable options. They are designed for long-lasting performance, remain free of calcification, don´t require blood-thinning medication, and enhance endogenous in-situ tissue regeneration.
OneValveTric is a Biomimetic Polymeric, non-resorbable, Transcatheter Tricuspid Heart Valve prosthesis. This next-gen Transcatheter Tricuspid Heart Valve is highly resistant to degeneration and thrombosis and offers additional unique features, such as an ultra-low-profile catheter and cardiac electrical conduction system management.
NAI Senior Members are active faculty, scientists and administrators from NAI member insti...
The Society For Biomaterials hosted its 2022 Annual Meeting at the Baltimore Marriott Wate...
Neoolife Inc. Awarded NIH Grant and Reaches Key Development Milestone with Successful 6-mo...